Eloise D Austin1, Sean S Sullivan1, Nenad Macesic1,2, Monica Mehta3, Benjamin A Miko1, Saman Nematollahi4, Qiuhu Shi5, Franklin D Lowy1,6, Anne-Catrin Uhlemann1,7. 1. Department of Medicine, Division of Infectious Diseases, Columbia University Irving Medical Center, New York, New York. 2. Department of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia. 3. Department of Pharmacy, New York Presbyterian Hospital, New York. 4. Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Department of Public Health, School of Health Sciences and Practice, New York Medical College, Valhalla. 6. Department of Pathology and Cell Biology, Clinical Microbiology Laboratory, Columbia University Medical Center, New York, New York. 7. Department of Medicine Microbiome & Pathogen Genomics Core, Columbia University Medical Center, New York, New York.
Abstract
BACKGROUND: Understanding the changing epidemiology of Staphylococcus aureus bacteremia, as well as the variables associated with poor outcomes, can yield insight into potential interventions. METHODS: This study was a retrospective, observational cohort study of adult patients at an academic medical center in New York City who had S. aureus bloodstream infections between 1 January 2007 and 31 December 2015. Participants were divided into 3 periods: group 1 (2007-2009), group 2 (2010-2012), and group 3 (2013-2015) for trend analysis. All clinical strains were genotyped (spa.). The main outcome was 30-day all-cause mortality. RESULTS: There were 1264 episodes of methicillin-susceptible S. aureus (MSSA) and 875 episodes of methicillin-resistant S. aureus (MRSA) bacteremia, with a rising proportion due to MSSA (55% group 1; 59% group 2; 63% group 3; P = .03.) There were no significant changes in average age, gender, Charlson score, and distribution of strain genotypes. Mortality in MRSA infection was unchanged (25% group 1; 25% group 2; 26% group 3), while mortality in MSSA infection significantly declined (18% group 1; 18% group 2; 13% group 3). The average time to antistaphylococcal therapy (AST) in MSSA infection declined during the study (3.7 days group 1; 3.5 group 2; 2.2 group 3). In multivariate analysis, AST within 7 days of initial positive MSSA culture was associated with survival. CONCLUSIONS: Mortality in MSSA bloodstream infection is declining, associated with a decrease in time to targeted therapy. These results emphasize the potential for rapid diagnostics and early optimization of treatment to impact outcomes in MSSA bacteremia.
BACKGROUND: Understanding the changing epidemiology of Staphylococcus aureus bacteremia, as well as the variables associated with poor outcomes, can yield insight into potential interventions. METHODS: This study was a retrospective, observational cohort study of adult patients at an academic medical center in New York City who had S. aureus bloodstream infections between 1 January 2007 and 31 December 2015. Participants were divided into 3 periods: group 1 (2007-2009), group 2 (2010-2012), and group 3 (2013-2015) for trend analysis. All clinical strains were genotyped (spa.). The main outcome was 30-day all-cause mortality. RESULTS: There were 1264 episodes of methicillin-susceptible S. aureus (MSSA) and 875 episodes of methicillin-resistant S. aureus (MRSA) bacteremia, with a rising proportion due to MSSA (55% group 1; 59% group 2; 63% group 3; P = .03.) There were no significant changes in average age, gender, Charlson score, and distribution of strain genotypes. Mortality in MRSA infection was unchanged (25% group 1; 25% group 2; 26% group 3), while mortality in MSSA infection significantly declined (18% group 1; 18% group 2; 13% group 3). The average time to antistaphylococcal therapy (AST) in MSSA infection declined during the study (3.7 days group 1; 3.5 group 2; 2.2 group 3). In multivariate analysis, AST within 7 days of initial positive MSSA culture was associated with survival. CONCLUSIONS: Mortality in MSSA bloodstream infection is declining, associated with a decrease in time to targeted therapy. These results emphasize the potential for rapid diagnostics and early optimization of treatment to impact outcomes in MSSA bacteremia.
Authors: R S McClelland; V G Fowler; L L Sanders; G Gottlieb; L K Kong; D J Sexton; K Schmader; K D Lanclos; R Corey Journal: Arch Intern Med Date: 1999-06-14
Authors: O Gasch; M Camoez; M A Dominguez; B Padilla; V Pintado; B Almirante; C Martín-Gandul; F López-Medrano; E Ruiz de Gopegui; J Ramón Blanco; G García-Pardo; E Calbo; J P Horcajada; A Granados; A Jover-Sáenz; C Dueñas; M Pujol Journal: Clin Microbiol Infect Date: 2013-08-28 Impact factor: 8.067
Authors: N Fernández-Hidalgo; A Ribera; M N Larrosa; E Viedma; J Origüen; A de Alarcón; M C Fariñas; C Sáez; C Peña; E Múñez; M V García López; J Gavaldà; D Pérez-Montarelo; F Chaves; B Almirante Journal: Clin Microbiol Infect Date: 2017-12-18 Impact factor: 8.067
Authors: Achim J Kaasch; Gavin Barlow; Jonathan D Edgeworth; Vance G Fowler; Martin Hellmich; Susan Hopkins; Winfried V Kern; Martin J Llewelyn; Siegbert Rieg; Jesús Rodriguez-Baño; Matthew Scarborough; Harald Seifert; Alex Soriano; Robert Tilley; M Estée Tőrők; Verena Weiß; A Peter R Wilson; Guy E Thwaites Journal: J Infect Date: 2013-11-16 Impact factor: 6.072
Authors: Kyung-Hwa Park; Kerryl E Greenwood-Quaintance; James R Uhl; Scott A Cunningham; Nicholas Chia; Patricio R Jeraldo; Priya Sampathkumar; Heidi Nelson; Robin Patel Journal: PLoS One Date: 2017-06-02 Impact factor: 3.240
Authors: Casey L Cazer; Lars F Westblade; Matthew S Simon; Reed Magleby; Mariana Castanheira; James G Booth; Stephen G Jenkins; Yrjö T Gröhn Journal: Antimicrob Agents Chemother Date: 2021-03-18 Impact factor: 5.191
Authors: Kyle C Molina; Taylor Morrisette; Matthew A Miller; Vanthida Huang; Douglas N Fish Journal: Antimicrob Agents Chemother Date: 2020-06-23 Impact factor: 5.191
Authors: Sara Pichtchoulin; Ingrid Selmeryd; Elisabeth Freyhult; Pär Hedberg; Jonas Selmeryd Journal: Ups J Med Sci Date: 2021-03-05 Impact factor: 2.384
Authors: Kamal Hamed; Marc Engelhardt; Mark E Jones; Mikael Saulay; Thomas L Holland; Harald Seifert; Vance G Fowler Journal: Future Microbiol Date: 2020-01-10 Impact factor: 3.165